Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Cetuximab by Eli Lilly and Co for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Cetuximab is under clinical development by Eli Lilly and Co and currently in Phase II for Cutaneous Squamous Cell Carcinoma...